2 Stocks For Surefire Gains: Cloud Peak Energy Inc. (CLD), Conatus Pharmaceuticals Inc. (CNAT)

0 analysts out of 7 Wall Street brokerage firms rate Cloud Peak Energy Inc. (NYSE:CLD) as a Buy, while 2 see it as a Sell. The rest 5 describe it as a Hold. CLD stock traded higher to an intra-day high of $0.501. At one point in session, its potential discontinued and the price was down to lows at $0.47. Analysts have set CLD’s consensus price at $0, effectively giving it a -100% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $2.25 (up 368.75% from current price levels).

It is expected that in Dec 2018 quarter CLD will have an EPS of $-0.22, suggesting a -37.5% growth. Yearly earnings are expected to rise by -16.28% to about $-0.5. As for the coming year, growth will be about 6%, lifting earnings to $-0.47. RSI after the last trading period was 51.15. CLD recorded a change of 6.67% over the past week and returned -32.43% over the last three months while the CLD stock’s monthly performance revealed a shift in price of -24.19%. The year to date (YTD) performance stands at 31.04%, and the bi-yearly performance specified an activity trend of -78.95% while the shares have moved -85.54% for the past 12 months.

Cloud Peak Energy Inc. (CLD) currently trades at $0.48, which is lower by -3.03% its previous price. It has a total of 79.49 million outstanding shares, with an ATR of around 0.06. The company’s stock volume dropped to 3.04 million, worse than 5.17 million that represents its 50-day average. A 5-day increase of about 6.67% in its price means CLD is now 31.04% higher on year-to-date. The shares had marked a $4.10 52-week high price and the 52 week low of $0.25. Overall, it has seen a growth rate of -85.54 over the last 12 months.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares depreciated -1.38% over the last trading period, taking overall 5-day performance up to 41.79%. CNAT’s price now at $2.85 is greater than the 50-day average of $2.04. Getting the trading period increased to 200 days, the stock price was seen at $3.74 on average. The general public currently hold control of a total of 29.15 million shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 30.86 million. The company’s management holds a total of 3.66%, while institutional investors hold about 27.4% of the remaining shares. CNAT share price finished last trade 37.91% above its 20 day simple moving average and its downbeat gap from 200 day simple moving average is -23.88%, while closing the session with 41.58% distance from 50 day simple moving average.

Conatus Pharmaceuticals Inc. (CNAT) shares were last observed trading -59.05% down the peak of $6.96. Last month’s price growth of 37.68% puts CNAT performance for the year now at 64.74%. Consequently, the shares price is trending higher by 147.83%, a 52-week worst price. However, it is losing value with -39.75% in the last 6 months. From a technical perspective, it appears more likely that the stock will experience a Bull Run market as a result of the strong support seen recently between $2.48 and $2.67. The immediate resistance area is now $3.02 Williams’s %R (14) for CNAT moved to 15.04 while the stochastic %K points at 83.75.

Estimated quarterly earnings for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) are around $-0.1 per share in three months through March with $-0.07 also the estimate for June quarter of the fiscal year. It means the growth is estimated at 41.18% and 53.33%, respectively. Analysts estimate full-year growth to be 37.29%, the target being $-0.37 a share. The upcoming year will see an increase in growth by percentage to -8.11%, more likely to see it hit the $-0.4 per share. The firm’s current profit margin over the past 12 months is -51.1%. CNAT ranks higher in comparison to an average of -91.33% for industry peers; while the average for the sector is 0.56%.